Biotechnology

Compugen

Compugen released FY2026 Q1 earnings on May 18 Pre-Market EST, actual revenue USD 2.176 M (forecast USD 1.257 M), actual EPS USD -0.0811 (forecast USD -0.074)

Compugen to Release FY2026 Q1 Earnings on May 18 Pre-Market EST, Forecast Revenue USD 1.257 M, EPS USD -0.074

Compugen released FY2025 annual earnings on March 2 Pre-Market (EST), actual revenue USD 72.76 M (forecast USD 19.71 M), actual EPS USD 0.3783 (forecast USD -0.172)

Compugen released FY2025 Q4 earnings on March 2, Pre-Market (EST), actual revenue USD 67.33 M (forecast USD 14.3 M), actual EPS USD 0.6027 (forecast USD 0.05)

Compugen to Release FY2025 Q4 Earnings on March 2, 2026, Pre-Market EST; Forecast Revenue USD 14.3 M, EPS USD 0.05

Truist Financial analyst reiterates buy rating on Compugen

Compugen released FY2025 9 Months Earnings on November 10 Pre-Market EST, with actual revenue of USD 5.432 M and EPS of USD -0.2309

Compugen released FY2025 Q3 earnings on November 10 Pre-Market EST, actual revenue USD 1.891 M (forecast USD 1.469 M), actual EPS USD -0.0746 (forecast USD -0.0866)

Compugen to Release FY2025 Q3 Earnings on November 10, Pre-Market EST; Forecast Revenue USD 1.469 M, EPS USD -0.0866

Compugen released FY2025 Q2 earnings on August 6 Pre-Market EST, actual revenue USD 1.257 M (forecast USD 3.952 M), actual EPS USD -0.08 (forecast USD -0.065)

Compugen released FY2025 Semi-Annual earnings on August 6 Pre-Market (EST), actual revenue USD 3.541 M, actual EPS USD -0.1562

Compugen to release FY2025 Q2 earnings on August 6, pre-market EST, with forecast revenue of USD 3.952 M and EPS of USD -0.065

Compugen Ltd. Reveals Breakthrough in AI Predictive Computational Research

Compugen to Present AI Cancer Research at European Association for Cancer Research Conference

Compugen released FY2025 Q1 earnings on May 19 Pre-Market (EST), actual revenue USD 2.284 M (forecast USD 3.704 M), actual EPS USD -0.0777 (forecast USD -0.055)

Compugen Reports Q1 2025 Earnings and Launches New Trials

Compugen to Release Quarterly Earnings Report

Compugen to release FY2025 Q1 earnings on May 19 Pre-Market EST, forecast revenue USD 3.704 M, EPS USD -0.055

Compugen Ltd. to Release First Quarter Financial Results

Compugen released FY2024 annual earnings on March 4 Pre-Market (EST), actual revenue 27.86 M USD (forecast 43.87 M USD), actual EPS -0.16 USD (forecast -0.0333 USD)

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

Earning Release

业绩披露

2026.05.18 (EST) Announced FY2026 Q1 Earning Release (USD) Revenue 2.176 M, Net Income -7.669 M, EPS -0.0811

GILD

CGEN

Compugen (NASDAQ:CGEN) is on track to report interim progression-free survival data from its MAIA-ovarian study in Q1 2027. The company highlighted its first-quarter 2026 results, emphasizing the significance of 2026 for advancing its lead program, COM701, in ovarian cancer. Compugen also noted progress in partnered programs with AstraZeneca and Gilead, including the rilvegostomig program and GS-0321, respectively, with potential milestone payments and royalties.

Market Beat

Gilead Sciences

AstraZeneca PLC

AstraZeneca

Compugen Q1 Earnings Call Highlights

NVDA

09888

BIDU

This week, major companies including Nvidia, Nio, Walmart, Home Depot, and Baidu will report earnings. Options volatility is expected to rise ahead of these announcements, with significant price movements anticipated. For instance, Baidu's stock is expected to move +/- 7.88% on May 18, while Nvidia's is projected at +/- 7.52% on May 20. Investors should be aware of the risks associated with options trading and conduct thorough research.

- Several major companies, including Nvidia, Nio, Walmart, Home Depot, and Baidu, are scheduled to report earnings this week.  
- TipRanks has calculated the expected stock movements for these companies based on options volatility, which typically rises before earnings announcements due to uncertainty.  
- The expected moves range from +/- 4.98% for Walmart to +/- 73.51% for CATX, highlighting significant potential volatility after the announcements.

Tip Ranks

NVIDIA

BIDU-SW

Baidu

NIO Inc

NIO-SW

Walmart

Home Depot

Niu Tech 

Ceragon Networks

Perspective Therapeutics

Keysight Tech

Copart

Intuit

Perion Network

Star Bulk Carrier

Under Armour

Hut 8 Mining

AtaiBeckley

Sagimet Biosciences

Deckers Outdoor

Deere

Ross Stores

Take-Two Interactive Software

Workday

Weibo

WB-SW

Baozun

BAOZUN-W

Canaan

NVIDIA Corporation

NIO Inc. USD OV

BIDU-SWR

Under Armour-C

Options Volatility and Implied Earnings Moves This Week, May 18 – May 22, 2026

Compugen Reports First Quarter 2026 Results | CGEN Stock News

StockTitan

Compugen Reports First Quarter 2026 Results | CGEN Stock News

businessinsider

Compugen Q1 2026 Earnings Preview

GBIO

CBIO

SBIO

LABU

IBBQ

CGBIO has received FDA 510(k) clearance for its patient-specific titanium implant, EASYMADE TI, marking the first instance of a Korean company achieving this for a customized titanium implant in the U.S. market. Designed for cranial and craniofacial reconstruction, the implant is tailored using individual CT data and produced through advanced 3D printing technology. This clearance is expected to enhance CGBIO's expansion in the U.S. market, responding to the growing demand for personalized reconstruction solutions.

prnewswire

Generation Bio

Crescent Biopharma

ALPS Medical Breakthrough

Direxion S&P Biotech Bull 3X

VanEck Biotech ETF

Invesco Nasdaq Biotechnology ETF

iShares Biotechnology ETF

Proshares Ultra Nasdaq Biotech

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

Invesco Biotechnology & Genome ETF

08:00 ETCGBIO Receives FDA 510(k) Clearance for Patient-Specific Titanium Implant 'EASYMADE TI'

Compugen Ltd. CEO Eran Ophir sold 5,000 shares of stock at $2.90 each, totaling $14,500, representing a 30.53% decrease in his ownership. Following the sale, he holds 11,375 shares valued at approximately $32,987.50. The transaction was executed under a Rule 10b5-1 trading plan and disclosed to the SEC. Recently, Ophir also sold 5,625 shares at an average price of $2.21. Compugen's stock performance shows a market cap of $273.25 million and a P/E ratio of 7.81, with analysts giving it a consensus rating of "Moderate Buy."

Insider Selling: Compugen (NASDAQ:CGEN) CEO Sells 5,000 Shares of Stock

Compugen (NASDAQ:CGEN) presented its advancements in immuno-oncology at the Needham & Company Healthcare Conference, highlighting its AI-driven target discovery platform. CEO Eran Ophir discussed key clinical programs, including COM701 and COM902, and partnerships with AstraZeneca and Gilead. The company aims to activate the immune system against cancer, focusing on less inflamed tumors. Financially, Compugen has received significant funding from its collaborations, with potential for substantial milestone payments and royalties.

AstraZeneca PLC ADRhedged

VG Health

Compugen Highlights AI-Driven IO Pipeline, Key Trial Timelines and Big Pharma Partnerships at Needham Conference

Compugen Ltd. (NASDAQ: CGEN) will present at the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026, from 8:45-9:25 AM ET. A live webcast will be available on their Investor Relations website, with a replay following the event. Compugen focuses on cancer immunotherapy and utilizes AI/ML for drug target discovery, with several programs in various stages of development, including COM902 and rilvegostomig. Compugen's shares are traded on Nasdaq and the Tel Aviv Stock Exchange under CGEN.

Compugen to Participate in 25th Annual Needham Virtual Healthcare Conference | CGEN Stock News

Compugen Ltd. CEO Eran Ophir sold 5,625 shares at $2.21 each, totaling $12,431.25, reducing his ownership by 33.09%. Post-sale, he holds 11,375 shares valued at approximately $25,138.75. The transaction was made under a Rule 10b5-1 plan and disclosed to the SEC. Compugen's stock rose 2.7% to $2.26, with a market cap of $213.68 million. The company reported $0.60 EPS, exceeding estimates, and had a revenue of $67.33 million. Analysts have mixed ratings on the stock, with a consensus target price of $4.00.

Compugen (NASDAQ:CGEN) CEO Sells $12,431.25 in Stock

Compugen(CGEN.US)

Compugen Q1 Earnings Call Highlights

Options Volatility and Implied Earnings Moves This Week, May 18 – May 22, 2026

Compugen Reports First Quarter 2026 Results | CGEN Stock News

Compugen Q1 2026 Earnings Preview

08:00 ETCGBIO Receives FDA 510(k) Clearance for Patient-Specific Titanium Implant 'EASYMADE TI'

Insider Selling: Compugen (NASDAQ:CGEN) CEO Sells 5,000 Shares of Stock

Compugen Highlights AI-Driven IO Pipeline, Key Trial Timelines and Big Pharma Partnerships at Needham Conference

Compugen to Participate in 25th Annual Needham Virtual Healthcare Conference | CGEN Stock News

Compugen (NASDAQ:CGEN) CEO Sells $12,431.25 in Stock

Trending